Is Elderberry Good for COVID? What You Need to Know

Elderberry has not been clinically proven to prevent or treat COVID-19. Despite a surge of consumer interest during the pandemic and some intriguing laboratory findings, no large randomized trial has tested elderberry against SARS-CoV-2 in humans. The supplement’s reputation rests mostly on modest evidence from studies of influenza and the common cold, and on cell-culture experiments that cannot tell us what happens inside a living person. That gap between promise and proof is worth understanding before you reach for a bottle of elderberry syrup.

What Lab Studies Found Against SARS-CoV-2

A handful of in vitro experiments have looked at whether elderberry extracts can interfere with the virus that causes COVID-19. One study tested wild elderberry fruit and flower extracts and found they could block the binding between the SARS-CoV-2 spike protein and the ACE2 receptor on human cells in a dose-dependent way. The researchers reported that fruit extracts and flower extracts both showed inhibitory activity, with flower extracts being effective at lower concentrations.¹ The authors themselves noted that these results “require further validation” before anyone could draw conclusions about real-world use.

This kind of result is common in early-stage botanical research. Blocking a receptor in a dish is a long way from stopping an infection in a person. The concentrations needed in the test tube may be far higher than what your body can achieve after swallowing a supplement. And the virus itself has evolved considerably since these experiments were run, raising questions about whether findings based on the original spike protein apply to later variants.

Elderberry’s Track Record With Other Respiratory Viruses

Most of the clinical data on elderberry comes from studies of influenza and colds, not COVID-19. A systematic review that screened over a thousand records ultimately included just five randomized trials on elderberry for viral respiratory illness. The conclusion was cautious: elderberry may reduce the duration and severity of colds, and may shorten influenza, but the evidence is uncertain. The review also noted that elderberry did not appear to reduce the risk of catching a cold in the first place.² A separate meta-analysis of randomized controlled trials reached a somewhat more upbeat conclusion, finding that elderberry supplementation substantially reduced upper respiratory symptoms overall.³

An interesting detail from the systematic review is that when an elderberry-containing product was compared with oseltamivir (a prescription antiviral for flu), the elderberry product was associated with a lower risk of influenza complications and fewer adverse events.² That sounds impressive until you consider the total number of participants across these trials was small, and the study designs varied widely. The picture is one of plausible benefit, not proven benefit.

Even the strongest supporters of elderberry research acknowledge the evidence base is thin. Five randomized trials is not a lot to build clinical recommendations on, and none of those trials involved SARS-CoV-2. Drawing a line from “may shorten the flu by a day or two” to “useful against COVID-19” requires assumptions that the science has not yet tested.

How Elderberry Works in the Lab

Researchers have mapped out several ways elderberry extracts interfere with viruses in cell cultures. Against influenza, elderberry compounds appear to disrupt the lipid rafts that viruses use as platforms for entering and leaving cells. One study showed that higher doses of elderberry flavonoids significantly decreased both virus levels and viral protein production in infected human cells.⁴ Another found that elderberry had a mild inhibitory effect early in the influenza virus cycle but a considerably stronger effect in the post-infection phase, blocking viral glycoproteins and boosting the production of certain immune-signaling molecules.⁵

The active compounds behind these effects are mostly anthocyanins, a class of pigments that make elderberries dark purple. Elderberry is an unusually rich source; anthocyanins account for roughly 80 percent of its polyphenol content, and these polyphenols are what drive the berry’s antioxidant and anti-inflammatory properties.⁶ The challenge is getting those compounds from a test tube into the bloodstream at meaningful concentrations.

The Bioavailability Problem

Your body does not absorb elderberry anthocyanins the way it absorbs, say, caffeine or aspirin. The parent anthocyanins are poorly absorbed in the upper gut. Most of the action happens lower down, in the colon, where gut bacteria break the anthocyanins into a large family of smaller phenolic metabolites. A study of postmenopausal women who took elderberry supplements for 12 weeks identified 28 distinct anthocyanin metabolites in urine and 21 in plasma. The metabolites reached plasma concentrations roughly 36 times higher than the intact anthocyanins themselves.⁷

This means the compounds that actually circulate in your blood after taking elderberry are largely different from the ones tested in cell-culture antiviral experiments. Whether those metabolites retain antiviral activity is an open question. To make things more complicated, different people’s gut bacteria process elderberry anthocyanins in different ways. An experiment that incubated elderberry extract with three single bacterial strains found that each species broke the anthocyanins down through different metabolic pathways, producing different types and amounts of end products.⁸ In plain terms, two people taking the same elderberry supplement may end up with meaningfully different sets of active molecules in their blood.

The Cytokine Storm Concern

Early in the pandemic, a worry circulated online that elderberry could trigger a “cytokine storm,” the dangerous overreaction of the immune system that can make severe COVID-19 fatal. The concern was not baseless on its face: lab studies had shown that elderberry extracts boost the production of immune-signaling molecules like IL-6, and IL-6 was identified as a key driver of severe COVID-19 inflammation. The fear was that elderberry might pour gasoline on a fire your immune system had already started.

A review of the pros and cons of using elderberry for COVID-19 addressed this concern directly. The authors concluded that there is not yet enough evidence to support the claim that elderberry overstimulates the immune system to a dangerous degree. At the same time, they cautioned that further research is needed because elderberry could theoretically provoke a cytokine storm if given to someone who already has an active, severe infection.⁹ The same systematic review that looked at elderberry and respiratory viruses searched specifically for studies linking elderberry to clinical inflammatory outcomes and found none. It did find three studies measuring cytokine production in lab settings after people ingested elderberry, but those are not the same thing as demonstrating harm in a sick patient.²

The honest summary is that the cytokine storm risk from elderberry remains theoretical. No case report or clinical trial has documented it happening. But the absence of evidence is not evidence of absence, and if you are actively ill with a severe respiratory infection, adding an immune-stimulating supplement without medical advice is a gamble you probably do not need to take.

Safety Beyond Cytokines

Raw elderberries, bark, and leaves contain cyanogenic glycosides, compounds that can release small amounts of cyanide when chewed or digested. This sounds alarming, but thermal processing is very effective at reducing them. Heating can cut cyanogenic glycoside levels by about 44 percent in elderberry juice, 80 percent in tea, and as much as 96 percent in more heavily processed products like liqueur and spread.¹⁰ In American elderberry specifically, researchers have confirmed that the types and levels of cyanogenic glycosides are very low and pose no threat to consumers in fresh or processed products.¹¹ The practical takeaway: commercially processed elderberry supplements and syrups are not a cyanide risk, but eating handfuls of raw berries or making preparations from uncooked plant parts is not a good idea.

On drug interactions, the data is reassuring but incomplete. Small in vitro studies suggest elderberry has only weak inhibitory effects on CYP3A4, an enzyme that helps metabolize many medications.¹² A separate study found that elderberry had no apparent inhibition of UGT enzymes, another group involved in drug metabolism, and concluded that elderberry is unlikely to cause clinically significant herb-drug interactions through that pathway.¹³ That said, the CYP3A4 interaction, even if weak, was flagged in a case report involving a cancer patient on a targeted therapy drug. If you are on medications metabolized through CYP3A4, especially narrow-therapeutic-index drugs, mention your elderberry use to your prescriber.

The Product Quality Problem

Pandemic demand created a perfect storm for supplement quality issues. Elderberry supplement sales reached $320 million in the United States over 2020, driven by the perception that it could boost immunity against COVID-19.⁶ That surge in demand led to supply-chain strain, and with it, adulteration. A review of botanical supplement labeling found that top-selling ingredients including elderberry were increasingly marketed for immune health, but popular products were susceptible to adulteration with lower-grade ingredients, non-target plants, and synthetic compounds. Part of the problem was pandemic-related supply shortages, part was the same lax enforcement that plagues the dietary supplement industry generally.¹⁴

The FDA also took action against companies making explicit COVID-19 treatment claims about elderberry and other products. An analysis of FDA warning letters during the pandemic identified 182 letters issued for noncompliance related to marketing unapproved products for treatment, prevention, or testing of COVID-19. Several of these involved herbal products, including elderberry supplements.¹⁵ Selling elderberry syrup as a food or general wellness supplement is legal. Claiming it treats, cures, or prevents COVID-19 is not, because those claims have not been evaluated through the drug-approval process.

For consumers, the practical issue is straightforward: even if elderberry turns out to have some benefit, you cannot be sure the product you buy contains what the label says, at the concentration the label claims, from the species of elderberry that was used in the research. Third-party testing certifications can help, but they are voluntary and not universally adopted.

Elderberry’s Long History and Why It Does Not Settle the COVID Question

Elderberry’s medicinal use stretches back thousands of years across European and North American folk traditions. Flowers, fruits, bark, and leaves have been used for bronchitis, coughs, upper respiratory infections, and fever. Several pharmacopoeias have included dried elderberry flower for centuries.¹⁶ European black elder has been described as having nutritional and healing properties for as long as written records of herbalism exist.¹⁷

This deep traditional use is sometimes invoked as a reason to trust elderberry for new threats like COVID-19. The logic has obvious limits. Traditional herbalists were treating symptom clusters, not specific viral pathogens. A remedy that helps with “fever and cough” may work by making you feel more comfortable or by modestly supporting immune function, without having any meaningful effect on a particular virus’s replication. SARS-CoV-2 causes a disease with unique pathology, including vascular inflammation, blood-clotting abnormalities, and neurological effects that have no parallel in the ailments elderberry was traditionally used for. Historical use is a reasonable basis for further investigation, but it is not itself evidence of efficacy against a novel virus.

What Would Settle the Question

The evidence gap for elderberry and COVID-19 is not subtle. What would be needed to answer the question properly is a series of well-designed, placebo-controlled randomized trials in people with confirmed SARS-CoV-2 infection, using standardized elderberry preparations at defined doses, measuring outcomes like viral clearance, symptom duration, hospitalization, and inflammatory markers. As of now, no such trial has been published in a peer-reviewed journal. One small open-label study tested a branded elderberry extract on post-COVID symptoms in 74 subjects and reported improvements in physical and mental symptoms over 30 days, but this study was unblinded, used no placebo, and remains a preprint that has not undergone peer review, making it essentially a signal for future research rather than actionable evidence.¹⁸

Researchers studying elderberry for other respiratory viruses have pointed out that the methodological quality of existing trials is generally low, with small sample sizes, short durations, and inconsistent formulations. Until that changes, the honest answer to whether elderberry is good for COVID-19 is that we do not know. The biological plausibility exists. The lab data is encouraging in a limited way. The human data simply is not there yet. If you enjoy elderberry syrup in your tea, there is no particular reason to stop, but there is also no scientific basis for relying on it as protection against SARS-CoV-2 or as a treatment once you are infected.